A growing understanding of RNA biology is reshaping how scientists view the relationship between environmental toxicants, brain development, and neurodegenerative disease. A new review highlights the emerging importance of N6-methyladenosine (m6A), the most common RNA modification in cells, as a key regulator of nervous system development and a potential contributor to neurological damage caused by toxic environmental exposures.
Unlike changes to DNA itself, m6A modification influences how genetic information is processed after it is transcribed into RNA. By controlling the stability, translation and lifespan of messenger RNA, this reversible process helps regulate the formation and function of neurons, neural stem cells, and supporting glial cells, making it essential for normal brain development and maintenance.
The review describes how disruption of m6A regulation can interfere with the growth and specialization of neural stem cells, impair the formation of neuronal connections, alter myelin production, and influence immune activity within the brain. These widespread effects suggest that disturbances in RNA modification may have consequences across multiple stages of nervous system development and function.
The article also examines how abnormal m6A activity is associated with neurological conditions including Alzheimer's disease, Parkinson's disease, and epilepsy. Changes in RNA methylation appear to influence processes linked to memory, learning, neuronal survival, inflammation, oxidative stress and protein accumulation, providing a broader framework for understanding mechanisms involved in neurodegeneration.
A particular focus is the interaction between environmental toxicants and RNA modification. The review outlines evidence connecting alterations in m6A regulation with neurological damage associated with exposure to substances including manganese, arsenite, aluminum, cobalt, and the anesthetic sevoflurane. These toxicants affect different components of the m6A regulatory system, influencing pathways involved in neuronal survival, synaptic function, inflammation and cognitive performance.
The authors also discuss how manipulating m6A-related proteins may create new opportunities for protecting nerve cells and supporting recovery following neurological injury. Potential approaches include regulating enzymes that add or remove RNA methylation marks, as well as delivering therapeutic molecules using exosomes, which can cross the blood-brain barrier and target cells within the central nervous system.
By bringing together current knowledge on m6A modification, neurodevelopment, and toxicant-related neurodegeneration, the review underscores the growing importance of epitranscriptomic regulation in brain health. It provides an integrated overview of how environmental exposures may influence neurological disease through RNA-based mechanisms and identifies m6A as a promising avenue for future advances in the prevention and treatment of disorders affecting the nervous system.
